411 related articles for article (PubMed ID: 36555792)
21. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment.
Volkmann ER; McMahan Z
Curr Opin Rheumatol; 2022 Nov; 34(6):328-336. PubMed ID: 35993874
[TBL] [Abstract][Full Text] [Related]
22. The
Kavian N; Mehlal S; Jeljeli M; Saidu NEB; Nicco C; Cerles O; Chouzenoux S; Cauvet A; Camus C; Ait-Djoudi M; Chéreau C; Kerdine-Römer S; Allanore Y; Batteux F
Front Immunol; 2018; 9():1896. PubMed ID: 30177933
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin.
Park MJ; Park Y; Choi JW; Baek JA; Jeong HY; Na HS; Moon YM; Cho ML; Park SH
Exp Mol Med; 2022 Sep; 54(9):1577-1585. PubMed ID: 36175484
[TBL] [Abstract][Full Text] [Related]
24. The role of leukotrienes in the pathogenesis of systemic sclerosis.
Chwieśko-Minarowska S; Kowal K; Bielecki M; Kowal-Bielecka O
Folia Histochem Cytobiol; 2012 Jul; 50(2):180-5. PubMed ID: 22763975
[TBL] [Abstract][Full Text] [Related]
25. Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis.
Farina N; Campochiaro C; Lescoat A; Benanti G; De Luca G; Khanna D; Dagna L; Matucci-Cerinic M
Expert Rev Clin Immunol; 2023; 19(9):1131-1142. PubMed ID: 37366065
[TBL] [Abstract][Full Text] [Related]
26. Emerging targeted therapies in scleroderma lung and skin fibrosis.
Maurer B; Distler O
Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265
[TBL] [Abstract][Full Text] [Related]
27. Systemic sclerosis.
Asano Y
J Dermatol; 2018 Feb; 45(2):128-138. PubMed ID: 29226387
[TBL] [Abstract][Full Text] [Related]
28. Role of cellular senescence in the pathogenesis of systemic sclerosis.
Tsou PS; Shi B; Varga J
Curr Opin Rheumatol; 2022 Nov; 34(6):343-350. PubMed ID: 35979691
[TBL] [Abstract][Full Text] [Related]
29. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
[TBL] [Abstract][Full Text] [Related]
30. Serotonin and systemic sclerosis. An emerging player in pathogenesis.
Sagonas I; Daoussis D
Joint Bone Spine; 2022 May; 89(3):105309. PubMed ID: 34800695
[TBL] [Abstract][Full Text] [Related]
31. Role of Alarmins in the Pathogenesis of Systemic Sclerosis.
Giovannetti A; Straface E; Rosato E; Casciaro M; Pioggia G; Gangemi S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679721
[TBL] [Abstract][Full Text] [Related]
32. Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy.
Distler O; Cozzio A
Semin Immunopathol; 2016 Jan; 38(1):87-95. PubMed ID: 26577237
[TBL] [Abstract][Full Text] [Related]
33. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status.
Natalello G; Bosello SL; Paroni Sterbini F; Posteraro B; De Lorenzis E; Canestrari GB; Gigante L; Verardi L; Ferraccioli G; Sanguinetti M; Gremese E
Clin Exp Rheumatol; 2020; 38 Suppl 125(3):73-84. PubMed ID: 32865168
[TBL] [Abstract][Full Text] [Related]
34. E3 ubiquitin ligase: A potential regulator in fibrosis and systemic sclerosis.
Huang XL; Zhang L; Duan Y; Wang YJ; Zhao JH; Wang J
Cell Immunol; 2016; 306-307():1-8. PubMed ID: 27406900
[TBL] [Abstract][Full Text] [Related]
35. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
[No Abstract] [Full Text] [Related]
36. T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities.
Del Galdo F; Artlett CM
Curr Rheumatol Rep; 2006 Apr; 8(2):123-30. PubMed ID: 16569371
[TBL] [Abstract][Full Text] [Related]
37. Pharmacotherapy of systemic sclerosis.
Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
[TBL] [Abstract][Full Text] [Related]
38. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.
Kumar S; Singh J; Rattan S; DiMarino AJ; Cohen S; Jimenez SA
Aliment Pharmacol Ther; 2017 Apr; 45(7):883-898. PubMed ID: 28185291
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
40. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease.
Andréasson K; Alrawi Z; Persson A; Jönsson G; Marsal J
Arthritis Res Ther; 2016 Nov; 18(1):278. PubMed ID: 27894337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
